JOSEPH JANKOVIC to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Randomized Controlled Trials as Topic.
Connection Strength
0.745
-
Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis. Mov Disord Clin Pract. 2024 Oct; 11(10):1195-1202.
Score: 0.162
-
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. 2020 10; 17(4):1681-1693.
Score: 0.123
-
Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease? Nat Rev Neurol. 2017 Nov; 13(11):643-644.
Score: 0.100
-
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
Score: 0.091
-
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
Score: 0.089
-
Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008 Mar; 63(3):267-9.
Score: 0.052
-
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul; 20(7):981-90.
Score: 0.040
-
Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
Score: 0.024
-
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9:1913-26.
Score: 0.021
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013 Jun 01; 67:141-52.
Score: 0.018
-
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989; 4(4):303-9.
Score: 0.014
-
The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
Score: 0.012